Buy & Sell Incyte Corporation (INCY) – Incyte Corporation Price Today
Aura AI Summary
Key Stats
- $21.54BMarket Cap
- HealthSector
- -8.05%3M Drawdown
- $17.57BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 29 daysTypical Hold Time
Incyte Corporation (INCY) is currently valued at a market capitalization of $21.54B, with an enterprise value of $17.57B. Over the past 52 weeks, Incyte Corporation has traded between a low of $67.26 and a high of $110.57, highlighting its annual price range. Over the past three months, Incyte Corporation has recorded a drawdown of -8.05%, reflecting recent price volatility. On average, investors hold Incyte Corporation for approximately 29 days, indicating typical investor behavior on the platform.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...
